- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03876587
Pyrotinib Combined With Docetaxel in the First-line Treatment of HER2-positive MBC
March 12, 2019 updated by: Xiaojia Wang(xj wang), Zhejiang Cancer Hospital
A Multicenter, Phase II Open Label Study of Pyrotinib Maleate Combined With Docetaxel in the First-line Treatment of HER2-positive Metastatic Breast Cancer
To explore the efficacy and safety of pyrotinib combined with docetaxel regimen in the first-line treatment of HER2-positive metastatic breast cancer.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
A multi-center, one-arm, open label design study,which is planned to enroll 79 patients with HER2-positive metastatic breast cancer receiving first-line treatment with pyrotinib and docetaxel.
The main purpose of this study was to observe the efficacy and safety of first-line treatment with pyrrolidine and docetaxel for HER2-positive metastatic breast cancer.
Study Type
Interventional
Enrollment (Anticipated)
79
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310022
- Zhejiang Cancer Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Local recurrent or metastatic breast cancer suitable for chemotherapy, confirmed histologically.
- HER2-positive breast cancer(according to 2018 ASCO/CAP HER2 test guideline).
- do not chemotherapy for recurrent and metastatic lesions, but local treatment for local symptoms, such as radiotherapy for relieving bone pain, is allowed.
- if the patient is bilateral breast cancer, metastasis lesions must be HER2-positive.
- 18-70 years old.
- ECOG PS 0~1.
- life expectancy is not less than 12 weeks.
- at least one measurable lesion according to RECIST 1.1.
- Endocrine therapy is allowed to relapse/metastasis disease; patients with previous adjuvant/neoadjuvant use of Taxus and trastuzumab, disease-free interval from the end of last adjuvant/neoadjuvant Taxus therapy to the progression of tumors (≥12 months), and disease-free interval from the end of last adjuvant/neoadjuvant trastuzumab to the progression of tumors (≥ 6 months).
- ANC ≥ 1.5×109/L,PLT ≥ 75×109/L,Hb ≥ 100 g/L;TBIL≤1.0ULN;ALT and AST≤3×ULN(ALT and AST≤5×ULN if liver metastasis);BUN and Cr≤1.5×ULN and CCr≥50 mL/min.
- LVEF ≥ 50% and QTc≤480 ms.
- known hormone receptor status.
- Signed informed
Exclusion Criteria:
- Central nervous system metastasis.
- Unable to swallow, chronic diarrhea and intestinal obstruction, there are many factors affecting drug use and absorption.
- patient who received radiotherapy, chemotherapy, surgery (excluding local puncture) or molecular targeted therapy within 4 weeks before admission; those who received anti-tumor endocrine therapy after screening period
- Participated in other drug clinical trials within 4 weeks before admission
- Tyrosine kinase inhibitors targeting HER2 (Neratinib, Lapatinib, pyrotinib, etc.) have been used or are being used in the past.
- Other malignant tumors, excluding cured cervical carcinoma in situ, skin basal cell carcinoma or skin squamous cell carcinoma, have been diagnosed in the past five years.
- Receive other antitumour treatment at the same time
- A history of immunodeficiency, including HIV positive, HCV, active hepatitis B, or other acquired, congenital immunodeficiency disorders, or organ transplantation, is known.
- Has suffered from any heart disease
- Female patients during pregnancy and lactation, fertile women with positive baseline pregnancy tests or women of childbearing age who are unwilling to take effective contraceptive measures throughout the trial
- According to the judgement of the researchers, there are concomitant diseases that seriously endanger the safety of patients or affect the completion of research (including, but not limited to, severe hypertension, severe diabetes, active infections, etc.).
- The patient did not recover from the toxicity of previous treatment to grade 0-1 (except hair loss).
- History of neurological or psychiatric disorders
- Along with CYP3A4 inhibitors or inducers or drugs that are using to prolong the QT interval
- Researchers believe that patients are not suitable for any other situation in this study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Pyrotinib Maleate combine with Docetaxel
Pyrotinib Maleate combine with Docetaxel should be administrate to all subjects. Initial dose: Pyrotinib Maleate 400mg oral administration everyday plus Docetaxel 75mg per square of BSA every three weeks intravenous injection. |
Pyrotinib Maleate combine with Docetaxel as the first-line treatment to HER2-positive Metastatic Breast Cancer
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Response Rate
Time Frame: from enrollment to progression or death (for any reason), assessed up to 100 months
|
Ratio of CR and PR in all subjects
|
from enrollment to progression or death (for any reason), assessed up to 100 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PFS
Time Frame: from enrollment to progression or death (for any reason),assessed up to 100 months
|
Progression-Free Survival
|
from enrollment to progression or death (for any reason),assessed up to 100 months
|
DoR
Time Frame: The first evaluation of CR or PR to progression or death (for any reason),assessed up to 100 months
|
Duration of Response
|
The first evaluation of CR or PR to progression or death (for any reason),assessed up to 100 months
|
Clinical Benefit Rate
Time Frame: from enrollment to progression or death (for any reason),assessed up to 100 months
|
Ratio of CR,PR and SD greater than or equal to 24 weeks in all subjects
|
from enrollment to progression or death (for any reason),assessed up to 100 months
|
OS
Time Frame: from enrollment to death (for any reason).assessed up to 100 months
|
Overall Survival
|
from enrollment to death (for any reason).assessed up to 100 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
adverse event
Time Frame: from enrollment to 30 days after the last dose administrate
|
Adverse events are described in terms of CTC AE 5.0
|
from enrollment to 30 days after the last dose administrate
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ANTICIPATED)
March 1, 2019
Primary Completion (ANTICIPATED)
October 1, 2019
Study Completion (ANTICIPATED)
December 1, 2020
Study Registration Dates
First Submitted
March 11, 2019
First Submitted That Met QC Criteria
March 12, 2019
First Posted (ACTUAL)
March 15, 2019
Study Record Updates
Last Update Posted (ACTUAL)
March 15, 2019
Last Update Submitted That Met QC Criteria
March 12, 2019
Last Verified
March 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HR-BLTN-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
the data will be shared from the trial begin and for 10 years.
IPD Sharing Time Frame
from the trial begin and for 10 years.
IPD Sharing Access Criteria
every one
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Breast Cancer
-
GlycoMimetics IncorporatedTerminatedBreast Cancer | Breast Cancer Metastatic | HR+ Metastatic Breast CancerUnited States
-
Gilead SciencesRecruitingStudy of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors (ASCENT-J02)Advanced Solid Tumor | Metastatic Urothelial Cancer | Metastatic Triple-Negative Breast Cancer | HR+/HER2- Metastatic Breast CancerJapan
-
BriaCell Therapeutics CorporationRecruitingBreast Cancer | Breast Neoplasm | Metastatic Breast Cancer | Breast Cancer Metastatic | End Stage CancerUnited States
-
OBI Pharma, IncCompletedMetastatic Colorectal Cancer | Metastatic Lung Cancer | Metastatic Breast Cancer | Metastatic Gastric CancerTaiwan
-
Massachusetts General HospitalPuma Biotechnology, Inc.; Celcuity, Inc.WithdrawnMetastatic Breast Cancer | Invasive Breast Cancer | HER2-negative Breast Cancer | ER Positive Breast Cancer | PR-Positive Breast Cancer | Stage IV (Metastatic) Breast CancerUnited States
-
Novartis PharmaceuticalsCompletedMetastatic Breast Cancer | Postmenopausal Women | Locally Advanced Metastatic Breast CancerIsrael
-
Prof. Wolfgang JanniEli Lilly and CompanyRecruitingHormone Receptor-positive Metastatic Breast Cancer | HER2-negative Metastatic Breast CancerGermany, Switzerland
-
Institut de Recherches Internationales ServierADIR, a Servier Group companyCompletedMetastatic Breast Cancer | Metastatic Triple Negative Breast CancerJapan, Belgium, France, Netherlands
-
BriaCell Therapeutics CorporationLumaBridgeEnrolling by invitationBreast Cancer | Breast Neoplasm | Metastatic Breast Cancer | Breast Cancer MetastaticUnited States
-
Gustave Roussy, Cancer Campus, Grand ParisDaiichi SankyoRecruitingAdvanced Breast Cancer | HER2-positive Metastatic Breast Cancer | Breast Cancer Metastatic | HER2 Low Breast CarcinomaFrance
Clinical Trials on Pyrotinib Maleate combine with Docetaxel
-
Sun Yat-sen UniversityJiangsu HengRui Medicine Co., Ltd.Unknown
-
Jiangsu HengRui Medicine Co., Ltd.UnknownHER2 Positive Gastric CancerChina
-
xuexin heNot yet recruitingHER2-positive Breast Cancer
-
Jiangsu HengRui Medicine Co., Ltd.CompletedHealthy ParticipantsChina
-
The First Affiliated Hospital with Nanjing Medical...Jiangsu HengRui Medicine Co., Ltd.Recruiting
-
Sun Yat-sen UniversityRecruiting
-
Shanghai Junshi Bioscience Co., Ltd.TerminatedAdvanced or Metastatic Solid TumorsChina
-
Jiangsu HengRui Medicine Co., Ltd.UnknownHealthy Participants
-
The Second Affiliated Hospital of Shandong First...Recruiting
-
Riphah International UniversityCompletedMyocardial RevascularizationPakistan